Edwards Lifesciences Corp Stock Analysis
EW Stock | USD 67.76 1.60 2.42% |
Edwards Lifesciences Corp is undervalued with Real Value of 79.19 and Target Price of 91.33. The main objective of Edwards Lifesciences stock analysis is to determine its intrinsic value, which is an estimate of what Edwards Lifesciences Corp is worth, separate from its market price. There are two main types of Edwards Lifesciences' stock analysis: fundamental analysis and technical analysis.
The Edwards Lifesciences stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Edwards Lifesciences is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Edwards Stock trading window is adjusted to America/New York timezone.
Edwards |
Edwards Stock Analysis Notes
About 86.0% of the company shares are held by institutions such as insurance companies. The book value of Edwards Lifesciences was currently reported as 16.18. The company had not issued any dividends in recent years. Edwards Lifesciences Corp had 3:1 split on the 1st of June 2020. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 15700 people. To learn more about Edwards Lifesciences Corp call Michael Mussallem at 949 250 2500 or check out https://www.edwards.com.Edwards Lifesciences Quarterly Total Revenue |
|
Edwards Lifesciences Corp Investment Alerts
Over 86.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from kalkinemedia.com: Anatara Lifesciences Expands GaRP-IBS Clinical Trial Sites to Adelaide and Sunshine Coast, Drives Record Enrollments |
Edwards Lifesciences Corp Upcoming and Recent Events
6th of February 2024 Upcoming Quarterly Report | View | |
24th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Edwards Largest EPS Surprises
Earnings surprises can significantly impact Edwards Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2012-10-19 | 2012-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2012-04-24 | 2012-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2011-10-19 | 2011-09-30 | 0.07 | 0.06 | -0.01 | 14 |
Edwards Lifesciences Environmental, Social, and Governance (ESG) Scores
Edwards Lifesciences' ESG score is a quantitative measure that evaluates Edwards Lifesciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Edwards Lifesciences' operations that may have significant financial implications and affect Edwards Lifesciences' stock price as well as guide investors towards more socially responsible investments.
Edwards Lifesciences Thematic Classifications
In addition to having Edwards Lifesciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
HealthcareUSA Equities from Healthcare industry as classified by Fama & French | ||
Obamacare RepealLarge healthcare related equities associated with Obamacare | ||
Medical EquipmentUSA Equities from Medical Equipment industry as classified by Fama & French |
Edwards Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Fisher Asset Management, Llc | 2024-06-30 | 8.3 M | Fmr Inc | 2024-06-30 | 7.6 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 7.3 M | Ubs Asset Mgmt Americas Inc | 2024-06-30 | 5.9 M | Amvescap Plc. | 2024-06-30 | 5.9 M | Northern Trust Corp | 2024-06-30 | 5.7 M | Sands Capital Management, Llc | 2024-06-30 | 5.6 M | Hhg Plc | 2024-06-30 | 5.4 M | Legal & General Group Plc | 2024-06-30 | 5.4 M | Vanguard Group Inc | 2024-06-30 | 53.6 M | Blackrock Inc | 2024-06-30 | 51 M |
Edwards Market Capitalization
The company currently falls under 'Large-Cap' category with a market capitalization of 39.02 B.Edwards Profitablity
The company has Net Profit Margin (PM) of 0.66 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.29 %, which signifies that for every $100 of sales, it has a net operating income of $0.29.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.18 | 0.10 | |
Return On Capital Employed | 0.19 | 0.14 | |
Return On Assets | 0.15 | 0.08 | |
Return On Equity | 0.21 | 0.11 |
Management Efficiency
Edwards Lifesciences Corp has Return on Asset (ROA) of 0.1065 % which means that for every $100 of assets, it generated a profit of $0.1065. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1914 %, which means that it produced $0.1914 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.06 in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 11.08 | 11.63 | |
Tangible Book Value Per Share | 8.30 | 8.72 | |
Enterprise Value Over EBITDA | 25.92 | 16.91 | |
Price Book Value Ratio | 6.96 | 4.82 | |
Enterprise Value Multiple | 25.92 | 16.91 | |
Price Fair Value | 6.96 | 4.82 | |
Enterprise Value | 43.3 B | 45.4 B |
Effective management at Edwards Lifesciences has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Operating Margin 0.2911 | Profit Margin 0.6586 | Beta 1.12 | Return On Assets 0.1065 | Return On Equity 0.1914 |
Technical Drivers
As of the 15th of November 2024, Edwards Lifesciences shows the Coefficient Of Variation of 32829.95, downside deviation of 1.56, and Mean Deviation of 1.23. Edwards Lifesciences Corp technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Edwards Lifesciences Corp information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Edwards Lifesciences Corp is priced favorably, providing market reflects its regular price of 67.76 per share. Given that Edwards Lifesciences has jensen alpha of (0.04), we urge you to verify Edwards Lifesciences Corp's prevailing market performance to make sure the company can sustain itself at a future point.Edwards Lifesciences Corp Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Edwards Lifesciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Edwards Lifesciences Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Edwards Lifesciences Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edwards Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edwards Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edwards Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edwards Lifesciences Outstanding Bonds
Edwards Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edwards Lifesciences Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edwards bonds can be classified according to their maturity, which is the date when Edwards Lifesciences Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
EDWARDS LIFESCIENCES P Corp BondUS28176EAD04 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
Edwards Lifesciences Predictive Daily Indicators
Edwards Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Edwards Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 279755.0 | |||
Daily Balance Of Power | 0.6349 | |||
Rate Of Daily Change | 1.02 | |||
Day Median Price | 66.57 | |||
Day Typical Price | 66.97 | |||
Price Action Indicator | 1.99 | |||
Period Momentum Indicator | 1.6 |
Edwards Lifesciences Corporate Filings
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 4th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 16th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Edwards Lifesciences Forecast Models
Edwards Lifesciences' time-series forecasting models are one of many Edwards Lifesciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Edwards Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Edwards Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Edwards Lifesciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Edwards shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Edwards Lifesciences. By using and applying Edwards Stock analysis, traders can create a robust methodology for identifying Edwards entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.27 | 0.14 | |
Operating Profit Margin | 0.26 | 0.16 | |
Net Profit Margin | 0.23 | 0.25 | |
Gross Profit Margin | 0.77 | 0.54 |
Current Edwards Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Edwards analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Edwards analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
91.33 | Buy | 32 | Odds |
Most Edwards analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Edwards stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Edwards Lifesciences Corp, talking to its executives and customers, or listening to Edwards conference calls.
Edwards Stock Analysis Indicators
Edwards Lifesciences Corp stock analysis indicators help investors evaluate how Edwards Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Edwards Lifesciences shares will generate the highest return on investment. By understating and applying Edwards Lifesciences stock analysis, traders can identify Edwards Lifesciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 772.6 M | |
Long Term Debt | 597 M | |
Common Stock Shares Outstanding | 609.4 M | |
Total Stockholder Equity | 6.7 B | |
Tax Provision | 207.6 M | |
Quarterly Earnings Growth Y O Y | 7.161 | |
Property Plant And Equipment Net | 1.8 B | |
Cash And Short Term Investments | 1.6 B | |
Cash | 1.1 B | |
Accounts Payable | 201.4 M | |
Net Debt | -449.1 M | |
50 Day M A | 67.425 | |
Total Current Liabilities | 1.2 B | |
Other Operating Expenses | 4.3 B | |
Non Current Assets Total | 5.3 B | |
Forward Price Earnings | 27.4725 | |
Non Currrent Assets Other | 463.7 M | |
Stock Based Compensation | 139.4 M |
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.